Elsevier

Atherosclerosis

Volume 106, Issue 2, April 1994, Pages 235-240
Atherosclerosis

Research paper
Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia

https://doi.org/10.1016/0021-9150(94)90128-7Get rights and content

Abstract

Type III hyperlipoproteinemia (dysbetalipoproteinemia) is characterized by elevated concentrations of plasma cholesterol and triglycerides due to an increase in very low density lipoprotein (VLDL) remnant lipoproteins. In a retrospective analysis we observed that in 12 patients with this disorder, gemfibrozil reduced concentrations of total cholesterol, VLDL cholesterol and triglycerides by 48%, 72% and 68%, respectively. These changes were greater than those reported in a similar number of patients treated with clofibrate. Comparative data on the efficacy of different fibrates in this disorder are very limited; to assess this further we have compared the hypolipidemic effects of gemfibrozil (600 mg twice daily) and clofibrate (1 g twice daily) in six patients with well-characterized type III hyperlipoproteinemia. Baseline values were obtained after at least 8 weeks on diet and treatment values were obtained after 6 and 8 weeks of treatment with each drug. Treatment with clofibrate and gemfibrozil both resulted in significant reductions in the plasma concentrations of total cholesterol (40% and 54%), VLDL cholesterol (59% and 79%) and total triglycerides (48% and 70%), as well as a significant increase in HDL cholesterol (9% and 7%). Gemfibrozil was, however, significantly (P < 0.05) more effective in reducing plasma concentrations of total cholesterol, VLDL cholesterol and triglycerides than was clofibrate, in the same patients.

Cited by (20)

  • Enhanced antihyperlipidemic potential of gemfibrozil under co-administration with piperine

    2021, Current Research in Pharmacology and Drug Discovery
    Citation Excerpt :

    The body weights were recorded before and after the experiments to ensure the induction of hypercholesterolemia. The experiments were conducted for about 4 weeks and the groups received the following drug treatments: group 1 (NRML) served as the normal control; group 2 (HFF) served as the disease control and did not receive any drug treatment; group 3 (GEM) served as the drug control and received gemfibrozil alone at a dose of 20 ​mg/kg/day; group 4 (PIP) received piperine alone at a dose of 5 ​mg/kg/day; group 5 (GEM-PIP-5) received gemfibrozil and piperine at doses of 20 ​mg/kg/day and 5 ​mg/kg/day, respectively; group 6 (GEM-PIP-10) received gemfibrozil and piperine at doses of 20 ​mg/kg/day and 10 ​mg/kg/day, respectively; and group 7 (GEM-PIP-20) received gemfibrozil and piperine at doses of 20 ​mg/kg/day and 20 ​mg/kg/day, respectively [10]. The drugs were administered via oral garage in corn oil.

  • Fibrates

    2009, Clinical Lipidology: A Companion to Braunwald's Heart Disease
  • Fibrates

    2008, Clinical Lipidology: A Companion to Braunwald's Heart Disease Expert Consult: Online and Print
View all citing articles on Scopus

Present address: Department of Cardiology A, Aarhus Amtssygehus, Tage-Hansens Gade 2, DK-5000 Odense C, Denmark.

View full text